A Phase 3 interventional study of Tenofovir DF and TDF Placebo in Chronic Hepatitis B, sponsored by Gilead Sciences. Active, not recruiting at 21 sites in 5 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 34th largest by enrollment, is one of 8 that started in 2012, is one of 13 in phase 3, and was the 26th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 2 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 22
First in 2004; this study’s year is marked. 8 started in 2012.
This study's enrollment of 90 is close to the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 117 across the 50 interventional studies. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 50 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
34 studies in Hepatitis B, Chronic by Gilead Sciences: none open now, 2 under way, 1 of them phase 3. Of 31 finished, 24 (77%) have results posted.
Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, this one is the 19th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2012, is one of 8 in phase 3, and was the 20th registered.
Gilead Sciences’s Hepatitis B, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 34 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to \< 12 years at the time of enrollment) with chronic hepatitis B (CHB) infection.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tenofovir disoproxil fumarate (tenofovir DF; TDF) for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).
Drug: Tenofovir DF
Participants will receive TDF placebo for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).
Drug: TDF Placebo
Following 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3) of blinded randomized treatment, participants will switch to open-label TDF treatment for an additional 120 weeks (protocol amendment 2) or 144 weeks (protocol amendment 3).
Drug: Tenofovir DF
Following the completion of study at Week 192, participants may have the option to receive open-label TDF until it is commercially available in that country for treatment of chronic HBV in participants of their age and weight.
Drug: Tenofovir DF
* Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight). * Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg.
Also known as: Viread®
* Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily. * Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily.
Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Failure Approach)
Time frame: Week 48
Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Excluded Approach)
Time frame: Week 48
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48
HBeAg seroconversion was defined as HBeAg loss and a change from HBeAb negative or missing at baseline to HBeAb positive.
Time frame: Week 48
Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 48, Based on the American Association for the Study of Liver Diseases (AASLD) Normal Range
Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range.
Time frame: Week 48
Percentage of Participants With Normal ALT at Week 192, Based on the AASLD Normal Range
Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range.
Time frame: Week 192
Percentage of Participants With Normal ALT at Week 48, Based on the Central Lab Normal Range
Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range.
Time frame: Week 48
Percentage of Participants With Normal ALT at Week 192, Based on the Central Lab Normal Range
Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range.
Time frame: Week 192
Percentage of Participants With Normalized ALT at Week 48, Based on the AASLD Normal Range
Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Time frame: Week 48
Percentage of Participants With Normalized ALT at Week 192, Based on the AASLD Normal Range
Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Time frame: Week 192
Percentage of Participants With Normalized ALT at Week 48, Based on the Central Lab Normal Range
Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Time frame: Week 48
Percentage of Participants With Normalized ALT at Week 192, Based on the Central Lab Normal Range
Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Time frame: Week 192
Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 48
Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Time frame: Week 48
Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 192
Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Time frame: Week 192
Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 48
Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Time frame: Week 48
Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 192
Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Time frame: Week 192
Percentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 48
Time frame: Week 48
Percentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 192
Time frame: Week 192
Percentage of Participants With HBsAg Loss at Week 48
HBsAg Loss was defined as a change from HBsAg positive or missing at baseline to HBsAg negative.
Time frame: Week 48
Percentage of Participants With HBsAg Loss at Week 192
HBsAg Loss was defined as a change from HBsAg positive or missing at baseline to HBsAg negative.
Time frame: Week 192
Percentage of Participants With HBsAg Seroconversion at Week 48
HBsAg seroconversion was defined as HBsAg loss and a change from HBsAb negative or missing at baseline to HBsAb positive.
Time frame: Week 48
Percentage of Participants With HBsAg Seroconversion at Week 192
HBsAg seroconversion was defined as HBsAg loss and a change from HBsAb negative or missing at baseline to HBsAb positive.
Time frame: Week 192
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 48
Time frame: Baseline; Week 48
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 96
Time frame: Baseline; Week 96
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 144
Time frame: Baseline; Week 144
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 192
Time frame: Baseline; Week 192
Percentage of Participants With ≥ 4% Decrease From Baseline in Spine Bone Mineral Density (BMD) at Week 48
Time frame: Baseline; Week 48
Percentage of Participants With ≥ 4% Decrease From Baseline in Spine BMD at Week 192
Time frame: Baseline; Week 192
Percent Change From Baseline in BMD of Spine at Week 48
Time frame: Baseline; Week 48
Percent Change From Baseline in BMD of Spine at Week 192
Time frame: Baseline; Week 192
Participants were enrolled at study sites in the United States, Asia, and Europe.The first participant was screened on 06 December 2012. The last Week 192 study visit occurred on 02 June 2020.
| Milestone | Tenofovir Disoproxil Fumarate | Placebo |
|---|---|---|
| Started | 60 | 30 |
| Completed | 56 | 25 |
| Not completed | 4 | 5 |
| Withdrew: Participant noncompliance | 1 | 1 |
| Withdrew: Withdrew consent/assent | 3 | 3 |
| Withdrew: Randomized but not treated | 0 | 1 |
| Milestone | Tenofovir Disoproxil Fumarate | Placebo |
|---|---|---|
| Started | 56 | 25 |
| Completed | 35 | 11 |
| Not completed | 21 | 14 |
| Withdrew: Continuing study | 13 | 9 |
| Withdrew: Investigator decision | 2 | 1 |
| Withdrew: Withdrew consent/assent | 6 | 4 |
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Failure Approach) | 76.7 (64.0 to 86.6) | 6.9 (0.8 to 22.8) |
HBeAg seroconversion was defined as HBeAg loss and a change from HBeAb negative or missing at baseline to HBeAb positive.
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48 | 25.0 | 24.1 |
Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range.
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 48, Based on the American Association for the Study of Liver Diseases (AASLD) Normal Range | 51.7 | 17.2 |
Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range.
| percentage of participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Percentage of Participants With Normal ALT at Week 192, Based on the AASLD Normal Range | 71.7 | 51.7 |
Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range.
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Percentage of Participants With Normal ALT at Week 48, Based on the Central Lab Normal Range | 65.0 | 17.2 |
Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range.
| percentage of participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Percentage of Participants With Normal ALT at Week 192, Based on the Central Lab Normal Range | 80.0 | 62.1 |
Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Percentage of Participants With Normalized ALT at Week 48, Based on the AASLD Normal Range | 51.7 | 17.9 |
Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
| percentage of participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Percentage of Participants With Normalized ALT at Week 192, Based on the AASLD Normal Range | 71.7 | 50.0 |
Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Percentage of Participants With Normalized ALT at Week 48, Based on the Central Lab Normal Range | 65.5 | 14.8 |
Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
| percentage of participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Percentage of Participants With Normalized ALT at Week 192, Based on the Central Lab Normal Range | 79.3 | 59.3 |
Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 48 | 46.7 | 7.1 |
Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
| percentage of participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 192 | 70.0 | 42.9 |
Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 48 | 53.4 | 7.4 |
Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
| percentage of participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 192 | 75.9 | 55.6 |
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Percentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 48 | 71.7 | 6.9 |
| percentage of participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Percentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 192 | 81.7 | 62.1 |
HBsAg Loss was defined as a change from HBsAg positive or missing at baseline to HBsAg negative.
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Percentage of Participants With HBsAg Loss at Week 48 | 3.3 | 3.4 |
HBsAg Loss was defined as a change from HBsAg positive or missing at baseline to HBsAg negative.
| percentage of participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Percentage of Participants With HBsAg Loss at Week 192 | 10.0 | 0 |
HBsAg seroconversion was defined as HBsAg loss and a change from HBsAb negative or missing at baseline to HBsAb positive.
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Percentage of Participants With HBsAg Seroconversion at Week 48 | 0 | 0 |
HBsAg seroconversion was defined as HBsAg loss and a change from HBsAb negative or missing at baseline to HBsAb positive.
| percentage of participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Percentage of Participants With HBsAg Seroconversion at Week 192 | 0 | 0 |
| Participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 48 | 5 | 7 |
| Participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 96 | 1 | 2 |
| Participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 144 | 1 | 0 |
| Participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 192 | 0 | 0 |
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Percentage of Participants With ≥ 4% Decrease From Baseline in Spine Bone Mineral Density (BMD) at Week 48 | 18.3 | 6.9 |
| percentage of participants | TDF to TDF | Placebo to TDF |
|---|---|---|
| Percentage of Participants With ≥ 4% Decrease From Baseline in Spine BMD at Week 192 | 18.3 | 6.9 |
| Percent change in spine BMD | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Percent Change From Baseline in BMD of Spine at Week 48 | 3.798 ± 5.9118 | 7.557 ± 4.9790 |
| Percent change in spine BMD | TDF to TDF | Placebo to TDF |
|---|---|---|
| Percent Change From Baseline in BMD of Spine at Week 192 | 19.168 ± 12.2805 | 26.085 ± 14.2586 |
| percentage of participants | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) |
|---|---|---|
| Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Excluded Approach) | 83.6 (71.2 to 92.2) | 7.7 (0.9 to 25.1) |
Collected over First dose date up to the Week 192 Data Cut for Open-Label Phase; Additional adverse event data will be reported after study is completed and final analysis is done.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TDF (Blinded Randomized Phase) | 0/60 (0%) | 10/60 (16.7%) | 38/60 (63.3%) |
| Placebo (Blinded Randomized Phase) | 0/30 (0%) | 2/29 (6.9%) | 16/29 (55.2%) |
| TDF to TDF (Open-Label Phase) | 0/56 (0%) | 8/56 (14.3%) | 21/56 (37.5%) |
| Placebo to TDF (Open-Label Phase) | 0/25 (0%) | 3/25 (12%) | 7/25 (28%) |
| Event | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) | TDF to TDF (Open-Label Phase) | Placebo to TDF (Open-Label Phase) |
|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 4/60 | 1/29 | 1/56 | 0/25 |
| AppendicitisInfections and infestations | 0/60 | 0/29 | 0/56 | 1/25 |
| BronchitisInfections and infestations | 0/60 | 0/29 | 0/56 | 1/25 |
| Hand-foot-and-mouth diseaseInfections and infestations | 0/60 | 0/29 | 0/56 | 1/25 |
| PharyngitisInfections and infestations | 0/60 | 0/29 | 1/56 | 1/25 |
| DehydrationMetabolism and nutrition disorders | 0/60 | 0/29 | 1/56 | 1/25 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/60 | 1/29 | 0/56 | 0/25 |
| Adenovirus infectionInfections and infestations | 0/60 | 0/29 | 1/56 | 0/25 |
| InfluenzaInfections and infestations | 0/60 | 0/29 | 1/56 | 0/25 |
| Meningitis viralInfections and infestations | 0/60 | 0/29 | 1/56 | 0/25 |
| Event | TDF (Blinded Randomized Phase) | Placebo (Blinded Randomized Phase) | TDF to TDF (Open-Label Phase) | Placebo to TDF (Open-Label Phase) |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 9/60 | 2/29 | 12/56 | 1/25 |
| Upper respiratory tract infectionInfections and infestations | 9/60 | 5/29 | 3/56 | 3/25 |
| PyrexiaGeneral disorders | 9/60 | 2/29 | 4/56 | 0/25 |
| PharyngitisInfections and infestations | 3/60 | 3/29 | 2/56 | 1/25 |
| Alanine aminotransferase increasedInvestigations | 3/60 | 3/29 | 0/56 | 0/25 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/60 | 1/29 | 0/56 | 1/25 |
| VomitingGastrointestinal disorders | 3/60 | 1/29 | 0/56 | 2/25 |
| HeadacheNervous system disorders | 2/60 | 2/29 | 2/56 | 0/25 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/60 | 2/29 | 0/56 | 0/25 |
| Abdominal painGastrointestinal disorders | 3/60 | 1/29 | 1/56 | 1/25 |
Safety Analysis Set: all randomized participants who received at least 1 dose of study drug. Participants were analyzed according to the treatment they actually received during the double-blind phase.
| Age, Continuous(years) | Tenofovir Disoproxil Fumarate | Placebo | Total |
|---|---|---|---|
| Mean | 6 ± 2.5 | 7 ± 3.2 | 6 ± 2.8 |
| Sex: Female, Male(Participants) | Tenofovir Disoproxil Fumarate | Placebo | Total |
|---|---|---|---|
| Female | 27 | 12 | 39 |
| Male | 33 | 17 | 50 |
| Ethnicity (NIH/OMB)(Participants) | Tenofovir Disoproxil Fumarate | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 60 | 29 | 89 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Tenofovir Disoproxil Fumarate | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 41 | 17 | 58 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 1 | 5 |
| White | 15 | 11 | 26 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Tenofovir Disoproxil Fumarate | Placebo | Total |
|---|---|---|---|
| South Korea | 23 | 11 | 34 |
| Romania | 13 | 10 | 23 |
| United States | 14 | 3 | 17 |
| Taiwan | 2 | 0 | 2 |
| India | 8 | 5 | 13 |
| HBV DNA(log10 IU/mL) | Tenofovir Disoproxil Fumarate | Placebo | Total |
|---|---|---|---|
| Mean | 8.089 ± 0.7208 | 8.133 ± 1.2538 | 8.103 ± 0.9214 |
| Hepatitis B Virus Surface Antigen (HBsAg)(Participants) | Tenofovir Disoproxil Fumarate | Placebo | Total |
|---|---|---|---|
| Positive | 60 | 29 | 89 |
| Negative | 0 | 0 | 0 |
| Hepatitis B e antigen (HBeAg)(Participants) | Tenofovir Disoproxil Fumarate | Placebo | Total |
|---|---|---|---|
| Positive | 56 | 29 | 85 |
| Negative | 4 | 0 | 4 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2012 to primary completion in Aug 2017, 56 months.
Results were first posted in Sep 2018, 1 year 1 month after primary completion.
Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 56 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir